Cumberland Pharmaceuticals Inc. ( (CPIX) ) has released its Q4 earnings. Here is a breakdown of the information Cumberland Pharmaceuticals Inc. presented to its investors.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company based in Tennessee, focuses on developing, acquiring, and commercializing unique products for hospital acute care, gastroenterology, and oncology markets.
Cumberland Pharmaceuticals reported an 11.6% increase in fourth-quarter 2024 revenue, reaching $10.4 million, with full-year revenue totaling $38 million. The company highlighted several strategic advancements, including expanded product labeling and key FDA designations.
Key financial metrics revealed a net loss of $1.9 million for the fourth quarter and $6.4 million for the year. Despite the losses, the company made significant strides in clinical development, notably with its Phase II study on ifetroban for Duchenne muscular dystrophy-related cardiomyopathy. Additionally, Cumberland’s antibiotic Vibativ received approval in China, expanding its international presence.
Cumberland’s management remains optimistic about 2025, emphasizing a focus on growth and delivering value to stakeholders. The company aims to continue advancing its mission of improving patient care through innovative pharmaceutical solutions.